Active ingredient: Dacomitinib.
Indication: First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
Dosage & Administration: 45 mg once daily until disease progression or unacceptable toxicity occurs.
Pfizer (Thailand) LTD
36-37 Fl United Center Bldg 323 Silom Rd, Kwang Silom Khet
Bangrak Bangkok 10500
Tel: (+66) 2761 4555 • (+66) 2761 4666 • Fax: (+66) 2635 5470